GeneFab Launches Cell-Specific Synthetic Promoters and Drug-Induced Switches to Enhance the Safety and Efficacy of In Vivo Cellular Therapies
- Pre-validated synthetic promoters drive expression in target cells while silencing it in off-target tissues.
- Drug-induced molecular switches give developers post-dose control of engineered cell activity.
- Designed for direct integration into clinical in vivo cell and gene therapy programs.
ALAMEDA, Calif. — May 4, 2026. GeneFab today announced the launch of a new toolkit of pre-validated synthetic promoters and drug-induced switches engineered specifically for in vivo cellular therapies. The tools are designed to enable safer, more precise, and clinically translatable cell and gene therapies — addressing two of the most persistent challenges innovators face when bringing in vivo programs forward: off-target expression and lack of post-dose control.
Why this matters
In vivo cell and gene therapies promise breakthrough treatments without the manufacturing complexity of ex vivo modalities — but the field has been held back by two interrelated problems. Constitutive promoters drive expression indiscriminately, leading to off-target activity in tissues where therapeutic payloads aren't needed and may cause harm. And once a patient is dosed, developers have no meaningful way to adjust or shut down activity if a safety signal emerges.
GeneFab's new toolkit addresses both gaps directly. Cell-specific promoters, validated in our screening pipeline against the most common target cell types for in vivo programs, drive payload expression only in cells where it's clinically needed. Drug-induced switches let developers tune — or terminate — engineered cell activity using clinically available small molecules.
How it works
The cell-specific promoters are a curated set of regulatory elements that drive expression in a defined target cell population and remain silent everywhere else. They've been benchmarked across cell types most relevant to current in vivo CGT programs — including hepatocytes, immune cells, and engineered stem-cell derivatives.
The drug-induced switches use clinically available, well-tolerated small molecules to gate transgene expression. Developers can choose between on-switches (turn expression on with the drug) and off-switches (turn it off), and tune the system for either pulsatile or sustained control.
Available now
All toolkit components are validated, manufacturing-ready, and available to GeneFab partners as part of program engagements — through Genetic Design services, viral vector manufacturing, or full CRDMO partnerships.